Literature DB >> 29255383

N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis.

Mostafa Saadat1.   

Abstract

A comprehensive literature search was conducted to identify all case-control studies investigating the association between GRIN1 G1001C polymorphism and schizophrenia susceptibility (MIM: 138249; dbSNP: rs 11146020). A total of 6 eligible studies (including 1639 schizophrenia cases and 1489 controls) were identified for the meta-analysis. Including all studies, there was significant heterogeneity between studies. In overall the GC (OR=1.00, 95 % CI: 0.0.85-1.19) and CC (OR=1.09, 95 % CI: 0.67-1.79) genotypes were not associated with schizophrenia risk compared with the GG genotype. In one study patients were diagnosed using DSM-IIIR criteria and in another study the genotypic frequencies of control subjects showed significant deviation from the expected frequencies according to the Hardy-Weinberg equilibrium. After excluding these studies from the meta-analysis, the heterogeneity between studies dramatically decreased. Statistical analysis showed that the GC genotype compared with the GG genotype significantly increased the risk of schizophrenia (OR=1.85, 95 % CI: 1.43-2.42, P<0.0001). The CC versus GG genotype significantly increased the schizophrenia risk (OR=2.46, 95% CI: 1.17-6.84, P=0.017). There was significant linear trend for presence of 0, 1, and 2 of the C allele and risk of schizophrenia (χ2=25.45, P<0.0001). In conclusion, the C variant allele may be associated with an increased risk for developing schizophrenia.

Entities:  

Keywords:  GRIN1; case-control study; genetic polymorphism; meta-analysis

Year:  2010        PMID: 29255383      PMCID: PMC5698899     

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


Introduction

Among many theories proposed for the pathogenesis of schizophrenia, dysfunction of the glutamate neurotransmitter system attracts much attention (Belsham, 2001[2]). Several genes that encode N-methyl-D-aspartate (NMDA) receptors have been cloned, including GRIN1 (MIM: 138249) (Brett et al., 1994[4]). Decreased expression of GRIN1 has been observed in various brain regions in schizophrenic patients (Sokolov, 1998[20]; Gao et al., 2000[7]; Ibrahim et al., 2000[10]). Also, reduced expression of Grin1 leads to behavioral abnormalities in mice that are similar to those observed in pharmacologically induced models of schizophrenia (Mohn et al., 1999[16]). In literature, several single nucleotide polymorphisms were described in GRIN1, including G1001C in the promoter region (dbSNP: rs 11146020). Previous studies investigating the association between this polymorphism and risk of schizophrenia have provided inconsistent results (Begni et al., 2003[1]; Martucci et al., 2003[15]; Qin et al., 2005[17]; Zhao et al., 2006[21]; Georgi et al., 2007[8]; Li et al., 2008[12]; Galehdari et al., 2009[6]; Betcheva et al., 2009[3]). The lack of concordance across the studies might have been due to individual studies, that have no sufficient statistical power to detect the effect of polymorphism on the schizophrenia susceptibility, differences between the study populations, or differences in the study design. Meta-analysis can summarize results from different studies by producing a single estimate of the major effect with enhanced precision. One of the major advantages of a meta-analysis is that it decreases the probability that random error will produce false-negative or false-positive association. Therefore, a meta-analysis could assist in estimating population-wide effects of polymorphisms in human disease and provide more reliable results than a single study. No meta-analysis investigating the association between GRIN1 G1001C polymorphism and susceptibility to schizophrenia has been conducted to date. Therefore the present study was done.

Materials and Methods

Literature search strategy

Eligible studies were identified by searching the MEDLINE (National Library of Medicine, Washington, DC, USA), Scopus, EBSCOhost Research Databases, ProQuest, EMBASE, Directory of Open Access Journals (DOAJ) and CAB Abstract for relevant reports before September 2009. Search terms were different combinations of “GRIN1”, “schizophrenia”, and “polymerphism”. The following criteria were used for the literature selection for the meta-analysis: (1) The article should be published in English; (2) Only case-control studies were considered; (3) The association study of G1001C polymorphism and schizophrenia risk were considered; (4) Only published articles in scientific journals were considered, therefore meeting abstracts and unpublished reports were not considered.

Data extraction

I extracted the following information from each article: author(s), year of publication, country of origin, criteria used for schizophrenia diagnosis, ethnicity, genotyping information, and number of cases and controls. For studies including subjects of different populations, data were extracted separately. Reports of Martucci et al. (2003[15]) and Betcheva et al. (2009[3]) were not included in the study because raw data were not mention in these articles. One study was not included in the analysis because the article was published in Chinese language (Li et al., 2008[12]). The report of Galehdari et al. (2009[6]) that included two different case-control groups was considered as two studies, in the meta-analysis. The application of these criteria yielded 6 case-control studies eligible for meta-analysis (Begni et al., 2003[1]; Qin et al., 2005[17]; Zhao et al., 2006[21]; Georgi et al., 2007[8]; Galehdari et al., 2009[6]).

Statistical analysis

Pearson's χ2 test was used to determine whether the observed frequencies of genotypes for control group in each study conformed to the Hardy-Weinberg equilibrium. The heterogeneity between studies was determined using Cochran's Q test, and the heterogeneity was considered significant for P<0.05. The strength of the associations between schizophrenia and the G1001C polymorphism was estimated by odds ratios (ORs) and 95 % confidence interval (CI). I estimated the risk of the genotypes GC and CC in comparison with the putative low risk GG genotype. A random effects model (DerSimonian and Laird, 1986[5]) was selected to pool data if there is significant heterogeneity, otherwise, the Mantel-Haenszel fixed effects model was used (Mantel and Haenszel, 1959[14]). Also the linear trend for presence of 0, 1, and 2 high risk variant allele (C allele) and risk of schizophrenia was performed using χ2 test. The P-value less than 0.05 considered statistically significant.

Results and Discussion

For the present meta-analysis 5 published articles dealing with 6 case-control studies were selected (Begni et al., 2003[1]; Qin et al., 2005[17]; Zhao et al., 2006[21]; Georgi et al., 2007[8]; Galehdari et al., 2009[6]). From these studies, 4, and 2 studies were carried out in Asian and European countries, respectively. Data were available from 6 studies, including 1639 patients and 1489 control subjects (Table 1(Tab. 1); References in Table 1: Begni et al., 2003[1]; Qin et al., 2005[17]; Zhao et al., 2006[21]; Georgi et al., 2007[8]; Galehdari et al., 2009[6]). The numbers in the case-control studies varied considerably (range 178 to 1373 individuals). In all of the studies, patients were diagnosed using DSM-IV criteria except one study that used DSM-IIIR criteria (Zhao et al. 2006[21]). In all studies the distribution of genotypes in the control group was consisted with Hardy-Weinberg equilibrium (Begni et al., 2003[1]; Qin et al., 2005[17]; Zhao et al., 2006[21]; Georgi et al., 2007[8]), except for one study (Galehdari et al., 2009[6]). There was significant difference in frequency of the variant C allele between Asian and European populations. Overall, the prevalence of the C allele among Asian controls was significantly higher than that in Caucasians (Table 1(Tab. 1)).
Table 1

Studies included in the meta-analysis

Including all studies, there was significant heterogeneity between the studies (Table 2(Tab. 2)). In overall, the GC genotype was not associated with schizophrenia risk compared with the GG genotype (OR=1.00, 95 % CI: 0.85-1.19). The same result obtained in comparison of CC versus GG genotypes (OR=1.09, 95 % CI: 0.67-1.79).
Table 2

Summary of meta-analysis of case-control studies examining GRIN1 G1001C polymorphism and schizophrenia risk

In order to find the source of heterogeneity between the studies, we excluded one case-control study from the Galehdari et al. (2009[6]) report, because its control group was not at Hardy-Weinberg equilibrium (χ2=39.50, df=1, P<0.0001). However, the heterogeneity did not decrease significantly. In the study of Zhao et al. (2006[21]) patients were diagnosed using DSM-IIIR criteria, whereas, in the other studies DSM-IV criteria was used. After excluding these studies from the analysis, the heterogeneity between the studies dramatically decreased (Table 2(Tab. 2)). Statistical analysis showed that the GC genotype compared with the GG genotype significantly increased the risk of schizophrenia (OR=1.85, 95 % CI: 1.43-2.42, P<0.0001). The CC versus GG genotypes significantly increased the schizophrenia risk (OR=2.46, 95 % CI: 1.17-6.84, P=0.017). There was significant linear trend for presence of 0, 1, and 2 of the C allele and risk of schizophrenia (χ2=25.45, P<0.0001). We know that schizophrenia is a multifactorial trait with multiple genetic and environmental factors that contribute to the risk of disorder. In pathogenesis of such traits the influence of genetic and environmental factors and also their interactions may be different between ethnic groups. Several meta-analyses indicated that some genetic polymorphisms might be associated with altered risk of some types of cancers in some ethnicity (Hu et al., 2005[9]; Kiyohara et al., 2006[11]; Saadat, 2006[18]; Saadat and Ansari-Lari, 2009[19]). Based on the present study the relationship between this genetic variation and schizophrenia risk among different ethnic groups is an open question. Because the authors of the original articles used in the present meta-analysis did not mention clearly whether they had used hospital based and/or population based controls or other risk factors for schizophrenia, stratification of the studies is impossible. It is strongly recommended that in future studies, the investigators considering the “STrengthening the REporting of Genetic Association studies (STREGA)” statement (Little et al., 2009[13]). It may be concluded that the relationship between the GRIN1 genotypic variation and susceptibility to schizophrenia is still an open question. In this field further larger case-control studies with multi-ethnic population are required.

Acknowledgements

The authors are indebted to Dr. Maryam Ansari-Lari for critical reading of the manuscript and for her contribution in discussion. This study was supported by Shiraz University.
  21 in total

1.  Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population.

Authors:  Elitza T Betcheva; Taisei Mushiroda; Atsushi Takahashi; Michiaki Kubo; Sena K Karachanak; Irina T Zaharieva; Radoslava V Vazharova; Ivanka I Dimova; Vihra K Milanova; Todor Tolev; George Kirov; Michael J Owen; Michael C O'Donovan; Naoyuki Kamatani; Yusuke Nakamura; Draga I Toncheva
Journal:  J Hum Genet       Date:  2009-01-16       Impact factor: 3.172

2.  Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics.

Authors:  B P Sokolov
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray.

Authors:  Shengying Qin; Xu Zhao; Yuxi Pan; Jianhua Liu; Guoyin Feng; Jingchun Fu; Jiying Bao; Zhizhou Zhang; Lin He
Journal:  Eur J Hum Genet       Date:  2005-07       Impact factor: 4.246

Review 5.  Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis.

Authors:  Chikako Kiyohara; Koichi Takayama; Yoichi Nakanishi
Journal:  Lung Cancer       Date:  2006-09-18       Impact factor: 5.705

6.  Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.

Authors:  A R Mohn; R R Gainetdinov; M G Caron; B H Koller
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

Review 7.  XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies.

Authors:  Zhibin Hu; Hongxia Ma; Feng Chen; Qingyi Wei; Hongbing Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

8.  Genomic cloning and localization by FISH and linkage analysis of the human gene encoding the primary subunit NMDAR1 (GRIN1) of the NMDA receptor channel.

Authors:  P M Brett; B Le Bourdelles; C G See; P J Whiting; J Attwood; K Woodward; M M Robertson; G Kalsi; S Povey; H M Gurling
Journal:  Ann Hum Genet       Date:  1994-05       Impact factor: 1.670

9.  Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population.

Authors:  Hamid Galehdari; Atefeh Pooryasin; Alimohammad Foroughmand; Setareh Daneshmand; Mostafa Saadat
Journal:  J Mol Neurosci       Date:  2008-09-16       Impact factor: 3.444

10.  Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample.

Authors:  Alexander Georgi; Rami Abou Jamra; Katrin Klein; Angela Wolf Villela; Johannes Schumacher; Tim Becker; Torsten Paul; Christine Schmael; Susanne Höfels; Norman Klopp; Thomas Illig; Peter Propping; Sven Cichon; Markus M Nöthen; Thomas G Schulze; Marcella Rietschel
Journal:  Psychiatr Genet       Date:  2007-10       Impact factor: 2.458

View more
  3 in total

1.  Exploratory study of selected nucleotide variants in GRIN1, GRIN2A and GRIN2B encoding subunits of the NMDA receptor in a targeted group of schizophrenia patients with chronic cognitive impairment.

Authors:  Marek Krzystanek; Marek Asman; Joanna Witecka; Artur Pałasz; Ryszard Wiaderkiewicz
Journal:  Pharmacol Rep       Date:  2020-11-25       Impact factor: 3.024

2.  Association between polymorphisms in the GRIN1 gene 5' regulatory region and schizophrenia in a northern Han Chinese population and haplotype effects on protein expression in vitro.

Authors:  Yong-Ping Liu; Mei Ding; Xi-Cen Zhang; Yi Liu; Jin-Feng Xuan; Jia-Xin Xing; Xi Xia; Jun Yao; Bao-Jie Wang
Journal:  BMC Med Genet       Date:  2019-01-31       Impact factor: 2.103

3.  Selected single-nucleotide variants in GRIN1, GRIN2A, and GRIN2B encoding subunits of the NMDA receptor are not biomarkers of schizophrenia resistant to clozapine: exploratory study.

Authors:  Marek Krzystanek; Marek Asman; Joanna Witecka; Artur Pałasz; Ryszard Wiaderkiewicz
Journal:  Pharmacol Rep       Date:  2020-10-06       Impact factor: 3.024

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.